Skip to main content

Table 1 Summary of participant characteristics by cancer type

From: Effects of cognitive-behavioral therapy for insomnia compared with controls among cancer survivors: a systematic review and meta-analysis of randomized trials

First author,

publication

year

N randomized

Mean age (years)

Women (%)

White race (%)

Sleep inclusion criteria

Predominant cancer typea

Cancer stage (%)c

Mean time since diagnosis (months, unless specified)

Mean years since treatment completion

Palesh,

2018 [26]

71

51

100

97

ISI

Breastb

I (20), II (55), III (23)

3

NR

Savard,

2016 [49]

242

55

100

NR

ISI

Breastb

I (52), II (28), III (16)

10

NR

Savard,

2014 [50]

242

53

100

NR

ISI

Breastb

I (49), II (34), III (13)

11

NR

Casault,

2015 [51]

38

57

95

NR

ISI

Breast

I-IV (specific stage not reported)

1.8 years

NR

Savard,

2005 [52]

58

55

100

100

DSM-IV

Breastb

I (58), II (37), III (5)

3.5 years

2.5

Dirksen,

2008 [53]

81

57

100

94

DSM-IV

Breastb

I (50), II (29), III (13)

4.8 years

4.8

Hall,

2022 [27]

40

51

90

90

DSM-IV, ISI

Breast

NR

7.8 years

5.1

Zhao,

2020 [54]

136

53

100

0

AASM

Breastb

I (26), II (54), III (20)

NR

2.3

Zachariae,

2018 [55]

255

53

100

NR

PSQI

Breastb

I (26), II (46), III (27)

NR

2.9

Ritterband,

2012 [56]

28

54

100

92

DSM-IV

Breast

I (46), II (21), III (18), IV (4)

NR

3.9

Roscoe,

2015 [57]

96

59

88

96

Self-reported/selected

Breast

NR

NR

4.5

Gonzalez,

2022 [58]

30

57

100

100

ISI

Breastb

NR

NR

½ to < 5, 1/2 to > 5

Espie,

2010 [59]

150

NR

69

NR

DSM-IV, PSQI

Breast

NR

NR

NR

Matthews,

2014 [60]

60

52

100

NR

ISI, SOL, WASO

Breastb

I (36), II (36), III (29)

NR

NR

Palesh,

2020 [61]

74

51

100

62

ISI, SDEF

Breastb

I (11), II (40), III (20), IV (26)

NR

N/A

Dean,

2020 [41]

40

66

63

81

ISI

Lungb

I (80), II (17)

8

NR

Padron,

2019 [62]

35

59

100

83

WASO, SOL

Gynecologicb

I (57), II (9), III (26), IV (3)

N/A

N/A

Zhang,

2019 [40]

70

58

100

0

WASO, SOL, SLE

Cervicalb

I (66), II (20), III (14)

3.5 years

NR

Chung,

2022 [63]

57

42

81

0

PSQI

Multiple

I (35), II (16), III (35), IV (8)

NR

NR

Summary

Total 1,803

Mean (range): 95 (28–255) participants

Mean (range): 55

(42–59) years

Mean (range): 94 (69–100) % women

Mean (range): 59

(0-100)% White race

ISI – 9 studies; DSM – 5 studies; PSQI – 3 studies; Other – 3 studies

15 breast or predominantly breast; 1 lung; 2 gynecologic, 1 mixed

Stage I-II: 20–80%

Stage III-IV: 3–35%

Mean (range): 2.7 years

(3 months – 7.8 years)

Mean (range): 3.7 (2.3–5.1) years

  1. a“Predominant” defined as > 50% of participants having the specified cancer type
  2. b100% of participants having the specified cancer type
  3. cPercentages do not necessarily add up to 100%, as some studies had participants with unknown or unreported cancer stage
  4. AASM = American Academy of Sleep Medicine; DSM-IV = Diagnostic & Statistical Manual of Mental Disorders, 4th edition; ISI = Insomnia Severity Index; NR = not reported; PSQI = Pittsburgh Sleep Quality Index; SDEF = Sleep Disruption Evaluation Form; SLE = Sleep Efficiency; SOL = Sleep Onset Latency; WASO = Wake After Sleep Onset
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us